Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jules Higué
Observed names:
Higué, Jules,
J. Higué,
Jules Higue
Institutions:
Walter and Eliza Hall Institute of Medical Research,
Centre Hospitalier Universitaire de Toulouse,
Institut universitaire du cancer de Toulouse Oncopole,
Université de Toulouse
Observed institutions:
Walter and Eliza Hall Institute of Medical Research,
Centre Hospitalier Universitaire de Toulouse,
Centre de Recherches en Cancérologie de Toulouse,
Institut universitaire du cancer de Toulouse Oncopole,
Université de Toulouse
ORCID:
0009-0004-4156-3165
Observed ORCID:
0009-0004-4156-3165
OpenAlex ID:
A5093098917
Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study
2024
·
C. Gallois
, E.S. Bergen
, et al.
·
ESMO Open
·
27
PDF
Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study
2025
·
Jules Higué
, Corentin Orvain
, et al.
·
Blood Cancer Journal
·
12
PDF
French Monocentric Experience of Outpatient Step-up Dosing of Teclistamab in Relapsed Refractory Multiple Myeloma
2023
·
Benjamin Hebraud
, Miguel Granell
, et al.
·
Blood
·
7
Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC ‐ DATAML ‐ MSKCC Retrospective Study
2025
·
Cassandre Petit
, Jules Higue
, et al.
·
American Journal of Hematology
·
4
PDF
625P Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
2023
·
C. Gallois
, M.E. Elez Fernandez
, et al.
·
Annals of Oncology
·
4
PDF
Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study
2026
·
Léopoldine Lapierre
, Lucie Laemmel
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
2
Real-World Evidence Supports Venetoclax as an Additional Option for Patients With t(11;14) Myeloma
2025
·
Jules Higué
, Gaetan Basile
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
2
Real-World Multicenter Data of Venetoclax Use in Multiple Myeloma with t(11-14). Time to Consider It Again
2024
·
Jules Higué
, Gaetan Basile
, et al.
·
Blood
·
2
Relationship between salvage strategy and outcomes in patients with CBF or NPM1 -mutated AML and first molecular relapse
2025
·
Corentin Orvain
, Jules Higue
, et al.
·
Blood Advances
·
1
Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study
2024
·
Jules Higué
, Corentin Orvain
, et al.
·
Blood
·
1
PDF
Venetoclax and Azacitidine for Molecular Relapse during First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Study from the Dataml Registry
2023
·
Jules Higué
, Pierre-Yves Dumas
, et al.
·
Blood
·
1
PDF
Neutropenia duration during AZA-VEN induction for AML is bimodal and correlates with infection risk
2026
·
Jules Higué
, Emily Batterham
, et al.
·
Blood Advances
PPM1D mutations confer resistance to venetoclax in pre-leukemic and AML populations
2025
·
Jules Higue
, Zhen Xu
, et al.
·
Blood
PDF
Identifying patients at risk of prolonged neutropenia and enhanced risk of complications during AZA-VEN induction for AML
2025
·
Emily Batterham
, Jules Higue
, et al.
·
Blood
Actualités cliniques et biologiques
2023
·
Nicoletti, Simon
, Cazabat, Romain
, et al.
·
Cairn.info
PDF
Show more works
View as search
Works count:
15
Citation count:
63
H-index:
4
I10-index:
2
Year
Topic
Type